COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals by Faksova, K., Walsh, D., Jiang, Y., Griffin, J., Phillips, A., Gentile, A., Kwong, J.C., Macartney, K., Naus, M., Grange, Z., Escolano, S., Sepulveda, G., Shetty, A., Pillsbury, A., Sullivan, C., Naveed, Z., Janjua, N.Z., Giglio, N., Perälä, J., Nasreen, S., Gidding, H., Hovi, P., Vo, T., Cui, F., Deng, L., Cullen, L., Artama, M., Lu, H., Clothier, H.J., Batty, K., Paynter, J., Petousis-Harris, H., Buttery, J., Black, S., Hviid, A.

Get full text

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study by Andersson, Niklas Worm, Thiesson, Emilia Myrup, Baum, Ulrike, Pihlström, Nicklas, Starrfelt, Jostein, Faksová, Kristýna, Poukka, Eero, Meijerink, Hinta, Ljung, Rickard, Hviid, Anders

Get full text

Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses by Andersson, Niklas Worm, Thiesson, Emilia Myrup, Baum, Ulrike, Pihlström, Nicklas, Starrfelt, Jostein, Faksová, Kristýna, Poukka, Eero, Lund, Lars Christian, Hansen, Christian Holm, Aakjær, Mia, Kjær, Jesper, Cohet, Catherine, Goossens, Mathijs, Andersen, Morten, Hallas, Jesper, Meijerink, Hinta, Ljung, Rickard, Hviid, Anders

Get full text